Rilpivirine
- Generic Name
- Rilpivirine
- Brand Names
- Complera, Edurant, Juluca, Odefsey, Rekambys
- Drug Type
- Small Molecule
- Chemical Formula
- C22H18N6
- CAS Number
- 500287-72-9
- Unique Ingredient Identifier
- FI96A8X663
- Background
Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance c...
- Indication
Rilpivirine, in combination with other agents, is indicated for the treatment of HIV-1 infections in antiretroviral treatment-naive patients with HIV-1 RNA ≤100,000 copies/mL and CD4+ cell count >200 cells/mm. The FDA combination therapy approval of rilpivirine and dolutegravir is indicated for adults and adolescents 12 years of age and older weighing at lea...
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1), Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2015-03-31
- Lead Sponsor
- Therapeutic Concepts
- Target Recruit Count
- 30
- Registration Number
- NCT02404233
- Locations
- 🇺🇸
Therapeutic Concepts, P.A., Houston, Texas, United States
🇺🇸Therapeutic Concepts, PA, Houston, Texas, United States
Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- PATH
- Target Recruit Count
- 136
- Registration Number
- NCT02165202
- Locations
- 🇿🇼
Spilhaus Clinical Research Site, Belgravia, Harare, Zimbabwe
🇺🇸Bronx Prevention Center, Bronx, New York, United States
🇿🇦Emavundleni Clinical Research Site, Cape Town, South Africa
Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age
A Study to Explore Pharmacokinetic Interaction Between Rilpivirine and Metformin in Healthy Participants
- First Posted Date
- 2012-11-01
- Last Posted Date
- 2014-03-06
- Lead Sponsor
- Janssen R&D Ireland
- Target Recruit Count
- 20
- Registration Number
- NCT01719614
A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment
- Conditions
- Interventions
- First Posted Date
- 2012-10-17
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 426
- Registration Number
- NCT01709084
A Study to Explore the Pharmacokinetics of Rilpivirine With Rifabutin in Healthy Participants
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Janssen R&D Ireland
- Target Recruit Count
- 20
- Registration Number
- NCT01615614
Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 40
- Registration Number
- NCT01585038
- Locations
- 🇺🇸
Indiana Clinical and Translational Sciences Institute, Indianapolis, Indiana, United States
The Rilpivirine Cerebrospinal-fluid (CSF) Study
- First Posted Date
- 2012-03-26
- Last Posted Date
- 2014-06-19
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 14
- Registration Number
- NCT01562886
- Locations
- 🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- Janssen R&D Ireland
- Target Recruit Count
- 482
- Registration Number
- NCT01266902
A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women
- Conditions
- Interventions
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2018-07-06
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 77
- Registration Number
- NCT00855335
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.